Flat-Colour.png

OneVentures Healthcare Fund III


In December 2016 OneVentures launched its $170M Healthcare Fund III. This Fund invests in therapeutics, devices and diagnostics at or near clinical development with a clear commercial, regulatory and reimbursement pathway; and well-defined value inflection and exit points on deal entry.

The fund will invest $10 to $20 million per company in Australian domiciled companies. The OneVentures team will provide support to drive these opportunities through the clinical, regulatory and reimbursement processes to achieve prominence in global markets.

The fund is licenced under the Commonwealth Government’s Biomedical Translation Fund (BTF) programme. The BTF programme was established to provide a pool of public and private funds for investment in promising biomedical innovations with commercialisation potential managed by leading Australian venture firms. OneVentures was granted an $85 million license supported by matching capital from its private investor network. The BTF funding provides benefits to investors both during the investment phase and on realisation.

 
 Food allergy therapeutics.  Led $15M Series A.  September 2016.

 Food allergy therapeutics.

 Led $15M Series A.

 September 2016.

 

OneVentures Innovation and Growth Fund II

 

The OneVentures Innovation and Growth Fund II was launched in October 2014 with $75M in funds available for investment in technology and healthcare businesses.

Fund II is focused on later stage companies seeking growth and development capital including for offshore expansion. Fund II is currently seeking technology companies with a strong product market fit and a clear path to revenue of $3 to 5M over the next 12 months. In particular, we are looking at investment opportunities where the experience of the OneVentures management team can be leveraged to accelerate value creation and company success. The fund looks to invest on average $5M and up to $10M into any one company.

 
Cloud-based HR platform. Led $4.5M Series A. July 2016.

Cloud-based HR platform.

Led $4.5M Series A.

July 2016.

Cancer DNA diagnostics. Led US$15M Series A. April 2016.

Cancer DNA diagnostics.

Led US$15M Series A.

April 2016.

Microprojection array (Nanopatch) for intradermal vaccine delivery. Led syndicate for $15M Series A financing, and $33M Series B financing. August 2011, February 2015.

Microprojection array (Nanopatch) for intradermal vaccine delivery.

Led syndicate for $15M Series A financing, and $33M Series B financing.

August 2011, February 2015.

 
Photo-realistic holographic technology platform. Contributed to a US$27M Series B financing led by Time Warner Investments. November 2016.

Photo-realistic holographic technology platform.

Contributed to a US$27M Series B financing led by Time Warner Investments.

November 2016.

Wearables for the vulnerable. Led $3M Series A. December 2015.

Wearables for the vulnerable.

Led $3M Series A.

December 2015.

 

OneVentures Innovation Fund I

 

The OneVentures Innovation Fund is a $40M venture capital fund established to provide capital and expertise to early stage (seed and Series A companies). This fund was launched in 2010 with the Commonwealth Government committing $20M from its Innovation Investment Fund programme matched by $20M capital from private sector investors. Capital from this fund is fully deployed.

Adaptive e-learning platform. Led Series A; $10M Series B; Led $5M C-Note financing October 2011, December 2013; July 2016.

Adaptive e-learning platform.

Led Series A; $10M Series B; Led $5M C-Note financing

October 2011, December 2013; July 2016.

Microprojection array (Nanopatch) for intradermal vaccine delivery. Led syndicate for $15M Series A financing, and $33M Series B financing. August 2011, February 2015.

Microprojection array (Nanopatch) for intradermal vaccine delivery.

Led syndicate for $15M Series A financing, and $33M Series B financing.

August 2011, February 2015.

Oncology information systems. Acquired by The Citadel Group (ASX:CGL). September 2017.

Oncology information systems.

Acquired by The Citadel Group (ASX:CGL).

September 2017.

Single application head lice treatment. Rights for human health applications in certain territories acquired by Dr.Reddy's for US$197M. September 2015.

Single application head lice treatment.

Rights for human health applications in certain territories acquired by Dr.Reddy's for US$197M.

September 2015.

Peak3.jpg
Video engagement platform. Led $4.9M Series A with participation by Intel and Warner Music October 2014.

Video engagement platform.

Led $4.9M Series A with participation by Intel and Warner Music

October 2014.

poloma.jpg
Building energy management software. Investment realised, IRR 70%. December 2012.

Building energy management software.

Investment realised, IRR 70%.

December 2012.